Status:
RECRUITING
Fibrosis Associated Protein Inhibitor (FAPI) Radiotracer-based Imaging to Identify Fibrotic Intestinal Crohn's Disease
Lead Sponsor:
University of Edinburgh
Conditions:
Crohn Disease
Eligibility:
All Genders
18-90 years
Brief Summary
Crohn's Disease (CD) is a chronic inflammatory condition that can affect any part of the intestine and currently has no cure. It affects 6.8 million people worldwide with UK healthcare costs in excess...
Eligibility Criteria
Inclusion
- Crohn's disease with ileal involvement (including those with disease recurrence in the neo-terminal ileum) due to commence biologics.
Exclusion
- Inability or unwilling to give informed consent.
- History of claustrophobia or feeling of inability to tolerate supine position for the PET/MRI or PET/CT scans.
- Impaired renal function with eGFR of \<30 mL/min/1.73m2
- Women who are pregnant or breastfeeding. Pregnancy test will be performed in all women of childbearing age
- Contrast allergy
- Contraindication to MRI (e.g. metallic implant or severe claustrophobia)
- Significant mental health conditions that will impair the ability to consent or affect their ability to take part in the study
- Patients with colonic disease only with no ileal or small bowel involvement.
- Contraindications (Glaucoma and/or ischaemic heart disease) or allergy (eg:
- anaphylaxis) to buscopan use.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07152431
Start Date
September 1 2024
End Date
August 1 2028
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHS Lothian
Edinburgh, United Kingdom